Skip to content
Screener

Prime Medicine PRME Q3 2025 earnings

Reported November 7, 2025 · Before market open

Revenue$1.2MMiss by $826.3K
EPS-$0.32Miss by $0.04
Revenue estimate$2.1M
EPS estimate-$0.28

Next report

Nov 6, 2026 (in 2 months)
Revenue estimate$1.3M
EPS estimate-$0.23

Financials

Q3 2025

Income statement

See full
Revenue$1.2M+486%
Operating income-$54.0M+0.5%
Net income-$50.6M+3.7%
EPS (diluted)-$0.32+27.3%

Balance sheet

See full
Cash & equivalents$85.1M-35.6%
Total debt$118.1M+186%
Total equity$161.8M-14.6%
Total assets$385.0M+15.7%

Cash flow

See full
Operating cash flow-$35.0M-35.2%
CapEx$247.0K-80.7%
Free cash flow-$35.3M-29.8%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$987.64M+114%
Enterprise value$1.02B+176%
P/S165.2×-411×

Profitability

See full
Operating margin-3,412.5%-1,597pp
Net margin-3,301.6%-1,545pp

Returns & leverage

See full
Return on equity-112.3%-1.9pp
Debt / equity0.7×+0.5×
Current ratio6.6×+0.1×

Segments

By segment

See full
Reportable Segment$1.2M+486%

FAQ

When did Prime Medicine report Q3 2025 earnings?
Prime Medicine (PRME) reported Q3 2025 earnings on November 7, 2025 before market open.
What were Prime Medicine's Q3 2025 revenue and EPS?
Prime Medicine reported revenue of $1.2M and eps of $-0.32 for Q3 2025.
Did Prime Medicine beat estimates in Q3 2025?
Revenue missed the consensus estimate of $2.1M by $826.3K. EPS missed the consensus estimate of $-0.28 by $0.04.
How did Prime Medicine's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 486.1% from $209.0K a year earlier and eps grew 27.3% from $-0.44.
Where can I find Prime Medicine's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-050415) and the 10-Q periodic report (0001628280-25-050422) directly on SEC EDGAR. The filing index links above go to sec.gov.